Skip to main content
Top
Published in: Clinical Drug Investigation 7/2013

Open Access 01-07-2013 | Original Research Article

Dose-Dependent Effect of Landiolol, a New Ultra-Short-Acting β1-Blocker, on Supraventricular Tachyarrhythmias in Postoperative Patients

Authors: Nobuyuki Taenaka, Shinichi Kikawa

Published in: Clinical Drug Investigation | Issue 7/2013

Login to get access

Abstract

Background

β-Adrenoceptor antagonists (β-blockers) have been reported to be effective for regulation of heart rate (HR) and restoring sinus rhythm in postoperative atrial fibrillation and atrial flutter, as well as in the prevention of those arrhythmias after open-heart surgery.

Objectives

The objectives of this study were to evaluate the dose-dependent effects of landiolol, an ultra-short-acting β1-blocker, as well as the effectiveness and safety of the drug in suppressing supraventricular tachyarrhythmias (SVT) in postoperative patients.

Methods

Landiolol was administered as a four-dose titration regimen (LL, L, M, and H doses) to postoperative patients who developed SVT. The titration sequence began with a 1-min loading infusion at a rate of 0.015 mg/kg/min, followed by a 10-min continuous infusion at 0.005 mg/kg/min (the LL dose). Infusions at progressively higher doses followed in sequence until 20 % reduction in HR was achieved. The L dose was a 1-min loading infusion at 0.03 mg/kg/min, followed by a 10-min continuous infusion at 0.01 mg/kg/min. The M dose was a 1-min loading infusion at 0.06 mg/kg/min, followed by a 10-min continuous infusion at 0.02 mg/kg/min. The H dose was a 1-min loading infusion at 0.125 mg/kg/min, followed by a 10-min continuous infusion at 0.04 mg/kg/min. The patient was then observed for 30 min to determine the cardiovascular responses to withdrawal of the medication. After completion of this follow-up period, additional maintenance infusion for up to 6 h was permitted if considered necessary by the investigator.

Results

A total of 108 patients were enrolled in this study. The cumulative improvement rates (percentage of patients obtaining ≥20 % reduction in HR) were 11.4, 32.4, 63.1, and 87.3 % at the LL, L, M, and H doses, respectively, demonstrating the dose-dependent effectiveness of landiolol. Additional infusion for up to 6 h was conducted in 16 patients. HR was maintained between 95.5 and 116.8 beats/min during the maintenance period (mean 259.8 min). Landiolol was generally well tolerated, although one patient with sick sinus syndrome developed an approximately 5-s cardiac arrest.

Conclusions

The overall results, including those pertaining to patient safety, demonstrate that landiolol is effective and useful for the treatment of postoperative SVT.
Appendix
Available only for authorised users
Literature
1.
go back to reference Halter JB, Pflug AE, Porte D. Mechanism of plasma catecholamine increases during surgical stress in man. J Clin Endocrinol Metab. 1977;45:936–44.PubMedCrossRef Halter JB, Pflug AE, Porte D. Mechanism of plasma catecholamine increases during surgical stress in man. J Clin Endocrinol Metab. 1977;45:936–44.PubMedCrossRef
2.
go back to reference Kalman JM, Munawar M, Howes LG, Louis WJ, Buxton BF, Gutteridge G, et al. Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg. 1995;60:1709–15.PubMedCrossRef Kalman JM, Munawar M, Howes LG, Louis WJ, Buxton BF, Gutteridge G, et al. Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg. 1995;60:1709–15.PubMedCrossRef
3.
go back to reference Breslow MJ, Jordan DA, Christopherson R, Rosenfeld B, Miller CF, Hanley DF, et al. Epidural morphine decreases postoperative hypertension by attenuating sympathetic nervous system hyperactivity. JAMA. 1989;261:3577–81.PubMedCrossRef Breslow MJ, Jordan DA, Christopherson R, Rosenfeld B, Miller CF, Hanley DF, et al. Epidural morphine decreases postoperative hypertension by attenuating sympathetic nervous system hyperactivity. JAMA. 1989;261:3577–81.PubMedCrossRef
4.
go back to reference Reves JG, Karp RB, Buttner EE, Tosone S, Smith LR, Samuelson PN, et al. Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man. Circulation. 1982;66(1):49–55.PubMedCrossRef Reves JG, Karp RB, Buttner EE, Tosone S, Smith LR, Samuelson PN, et al. Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man. Circulation. 1982;66(1):49–55.PubMedCrossRef
5.
go back to reference Leitch JW, Thomson D, Baird DK, Harris PJ. The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1990;100:338–42.PubMed Leitch JW, Thomson D, Baird DK, Harris PJ. The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1990;100:338–42.PubMed
6.
go back to reference Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg. 1993;56:539–49.PubMedCrossRef Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg. 1993;56:539–49.PubMedCrossRef
7.
go back to reference Hashimoto K, Ilstrup DM, Schaff HV. Influence of clinical and hemodynamic variables on risk of supraventricular tachycardia after coronary artery bypass. J Thorac Cardiovasc Surg. 1991;101:56–65.PubMed Hashimoto K, Ilstrup DM, Schaff HV. Influence of clinical and hemodynamic variables on risk of supraventricular tachycardia after coronary artery bypass. J Thorac Cardiovasc Surg. 1991;101:56–65.PubMed
8.
go back to reference Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVilet M, et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation. 1996;94:390–7.PubMedCrossRef Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVilet M, et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation. 1996;94:390–7.PubMedCrossRef
9.
go back to reference Olshansky B. Management of atrial fibrillation after coronary artery bypass graft. Am J Cardiol. 1996;78(8A):27–34.PubMedCrossRef Olshansky B. Management of atrial fibrillation after coronary artery bypass graft. Am J Cardiol. 1996;78(8A):27–34.PubMedCrossRef
10.
go back to reference Motohara T, Mayumi T, Kuroshima S, Takahashi T, Okushiba S, Kato H. Perioperative management for patients having cardiac disease—esophageal disease. ICU & CCU. 1995;19(7):575–81 (Japanese). Motohara T, Mayumi T, Kuroshima S, Takahashi T, Okushiba S, Kato H. Perioperative management for patients having cardiac disease—esophageal disease. ICU & CCU. 1995;19(7):575–81 (Japanese).
11.
go back to reference Matloff JM, Wolfson S, Gorlin R, Harken DE. Control of postcardiac surgical tachycardias with propranolol. Circulation. 1968;37(4 Suppl):II-133–8. Matloff JM, Wolfson S, Gorlin R, Harken DE. Control of postcardiac surgical tachycardias with propranolol. Circulation. 1968;37(4 Suppl):II-133–8.
12.
go back to reference Balser JR, Martinez EA, Winters BD, Perdue PW, Clarke AW, Huang W, et al. β-Adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology. 1998;89:1052–9.PubMedCrossRef Balser JR, Martinez EA, Winters BD, Perdue PW, Clarke AW, Huang W, et al. β-Adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology. 1998;89:1052–9.PubMedCrossRef
13.
go back to reference Gray RJ, Bateman TM, Czer LSC, Conklin CM, Matloff JM. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of HR in postoperative supraventricular tachyarrhythmias. J Am Coll Cardiol. 1985;5:1451–6.PubMedCrossRef Gray RJ, Bateman TM, Czer LSC, Conklin CM, Matloff JM. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of HR in postoperative supraventricular tachyarrhythmias. J Am Coll Cardiol. 1985;5:1451–6.PubMedCrossRef
14.
go back to reference Mooss AN, Wurdeman RL, Mohiuddin SM, Reyes AP, Sugimoto JT, Scott W, et al. Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery. Am Heart J. 2000;140:176–80.PubMedCrossRef Mooss AN, Wurdeman RL, Mohiuddin SM, Reyes AP, Sugimoto JT, Scott W, et al. Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery. Am Heart J. 2000;140:176–80.PubMedCrossRef
15.
go back to reference Daoud EG. Management of atrial fibrillation in the post-cardiac surgery setting. Cardiol Clin. 2004;22:159–66.PubMedCrossRef Daoud EG. Management of atrial fibrillation in the post-cardiac surgery setting. Cardiol Clin. 2004;22:159–66.PubMedCrossRef
16.
go back to reference Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery: a meta-analysis of randomized control trials. Circulation. 1991;84(3 Suppl):III-236–44. Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery: a meta-analysis of randomized control trials. Circulation. 1991;84(3 Suppl):III-236–44.
17.
go back to reference Kowey PR, Taylor JE, Rials SJ, Marinchak RA. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol. 1992;69:963–5.PubMedCrossRef Kowey PR, Taylor JE, Rials SJ, Marinchak RA. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol. 1992;69:963–5.PubMedCrossRef
18.
go back to reference Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β1-blocking agent in healthy volunteers. Rinshoiyaku. 2000;16(10):1531–56 (Japanese). Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β1-blocking agent in healthy volunteers. Rinshoiyaku. 2000;16(10):1531–56 (Japanese).
19.
go back to reference Shiroya T, Ichioka Y, Yosida K, Nishijima K, Oomawari N, Naka M, et al. Pharmacological studies of ONO-1101 as a β blocking agent with high β1 selectivity and ultra-short duration of action. Kiso to Rinsho. 1997;31(9):2913–23 (Japanese). Shiroya T, Ichioka Y, Yosida K, Nishijima K, Oomawari N, Naka M, et al. Pharmacological studies of ONO-1101 as a β blocking agent with high β1 selectivity and ultra-short duration of action. Kiso to Rinsho. 1997;31(9):2913–23 (Japanese).
20.
go back to reference Yoshiya I, Ogawa R, Okumura F, Shimada Y, Hanaoka K. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia—a phase III, double-blind study in comparison with placebo. Rinshoiyaku. 1997;13(19):4949–78 (Japanese). Yoshiya I, Ogawa R, Okumura F, Shimada Y, Hanaoka K. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia—a phase III, double-blind study in comparison with placebo. Rinshoiyaku. 1997;13(19):4949–78 (Japanese).
21.
go back to reference Yoshiya I, Ogawa R, Okumura F, Shimada Y, Kuro M. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia in patients with hypertension or cardiac ischemia—double-blind study in comparison with placebo. Rinshoiyaku. 2002;18(9):1049–76 (Japanese). Yoshiya I, Ogawa R, Okumura F, Shimada Y, Kuro M. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia in patients with hypertension or cardiac ischemia—double-blind study in comparison with placebo. Rinshoiyaku. 2002;18(9):1049–76 (Japanese).
22.
go back to reference Atarashi H, Kuruma A, Yashima M, Saitoh H, Ino T, Endoh Y, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting β-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000;68:143–50.PubMedCrossRef Atarashi H, Kuruma A, Yashima M, Saitoh H, Ino T, Endoh Y, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting β-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000;68:143–50.PubMedCrossRef
23.
go back to reference Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, Lai CM. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther. 1983;34:427–34.PubMedCrossRef Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, Lai CM. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther. 1983;34:427–34.PubMedCrossRef
24.
go back to reference Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, et al. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull (Tokyo). 1992;40:1462–9.CrossRef Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, et al. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull (Tokyo). 1992;40:1462–9.CrossRef
Metadata
Title
Dose-Dependent Effect of Landiolol, a New Ultra-Short-Acting β1-Blocker, on Supraventricular Tachyarrhythmias in Postoperative Patients
Authors
Nobuyuki Taenaka
Shinichi Kikawa
Publication date
01-07-2013
Publisher
Springer International Publishing AG
Published in
Clinical Drug Investigation / Issue 7/2013
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-013-0093-x

Other articles of this Issue 7/2013

Clinical Drug Investigation 7/2013 Go to the issue